证券记录 · 已归档季度
ORIC
ORIC Pharmaceuticals, Inc. · Healthcare · Biotechnology
10被追踪持有人
+1Δ持有人
12.33M持有股份
$68.78M报告持仓市值
+2新建仓位
−1清仓
动量输入（同类管理人）：
持有人广度 +11.1% ·
股份流向 +26.5% ·
净新建仓位 +10.0%
— 公式
广泛积累 — 持股数量上升且持有人增多
所有持股数据：仅限已追踪的 13F 管理人，普通股持仓，报告期 Q1 2025
持股变化趋势
| 季度 | 持有人 | Δ | 股份 | 报告持仓市值 | 新增 | 清仓 |
|---|---|---|---|---|---|---|
| Q2 2026 | 72 | 0 | 59.02M | $639.12M | +7 | −7 |
| Q1 2026 | 75 | +3 | 50.35M | $637.44M | +9 | −6 |
| Q4 2025 | 72 | +1 | 55.15M | $451.14M | +1 | — |
| Q3 2025 | 17 | 0 | 34.78M | $417.41M | — | — |
| Q2 2025 | 14 | +1 | 27.12M | $275.30M | +3 | −2 |
| Q1 2025 | 10 | +1 | 12.33M | $68.78M | +2 | −1 |
| Q4 2024 | 9 | -1 | 9.74M | $78.61M | — | −1 |
| Q3 2024 | 9 | 0 | 7.63M | $78.26M | +1 | −1 |
| Q2 2024 | 9 | — | 8.42M | $59.53M | — | — |
持有人 · Q1 2025
| # | 管理人 | 股份 | Δ股份 | 价值 | 其权重 | 持有 | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Viking Global Investors ✦ | 6.57M | +48.3% | $36.68M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 2 | State Street Global Advisors ✦ (被动) | 2.20M | +19.0% | $12.26M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 3 | T. Rowe Price ✦ | 1.33M | +2.9% | $7.44M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 4 | T. Rowe Price ✦ | 1.33M | +2.9% | $7.44M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 5 | Geode Capital Management ✦ (被动) | 1.31M | +2.1% | $7.29M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 6 | Geode Capital Management ✦ (被动) | 1.31M | +2.1% | $7.29M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 7 | Citadel Advisors ✦ | 511.89K | +1305.3% | $2.86M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 8 | Wellington Management ✦ | 178.22K | -4.4% | $994,451 | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 9 | Wellington Management ✦ | 178.22K | -4.4% | $994,451 | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 10 | Two Sigma Investments ✦ | 76.99K | -44.9% | $429,604 | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 11 | Millennium Management ✦ | 53.98K | +95.3% | $301,225 | 0.0% | ▲ Add | 4 | SEC ↗ |
| 12 | AQR Capital Management ✦ | 49.53K | 新增 | $276,376 | 0.0% | New | 1 | SEC ↗ |
| 13 | AQR Capital Management ✦ | 49.53K | 新增 | $276,376 | 0.0% | New | 1 | SEC ↗ |
| 14 | AQR Capital Management ✦ | 49.53K | 新增 | $276,376 | 0.0% | New | 1 | SEC ↗ |
| 15 | AQR Capital Management ✦ | 49.53K | 新增 | $276,376 | 0.0% | New | 1 | SEC ↗ |
| 16 | AQR Capital Management ✦ | 49.53K | 新增 | $276,376 | 0.0% | New | 1 | SEC ↗ |
| 17 | Marshall Wace ✦ | 47.70K | 新增 | $266,138 | 0.0% | New | 1 | SEC ↗ |
"持仓权重"= 该持仓占该管理人已申报13F股权价值的比例——即信念度衡量指标。✦ = 精选管理人。
新增买入方
| AQR Capital Management | $276,376 | 0.0% |
| AQR Capital Management | $276,376 | 0.0% |
| AQR Capital Management | $276,376 | 0.0% |
| AQR Capital Management | $276,376 | 0.0% |
| AQR Capital Management | $276,376 | 0.0% |
| Marshall Wace | $266,138 | 0.0% |
已清仓
| Adage Capital Partners | $4.04M | 曾为 0.0% |
全市场背景: 涵盖所有13F申报机构（SEC结构化数据， Q1 2026): 181 持有人, 119.04M 股份, $1.43B 已申报. 这是与上方被追踪全域数据不同的较早期间，两者从不混用。
常见共同持仓
该证券的被追踪持有人最常同时持有的其他证券——基于共同持有计数，而非基本面关联。
数据来源: 持股数据来源于已解析的13F普通股持仓（被追踪范围，变动对比集）；内部人行为来自Form 3/4/5；重大持股来自Schedule 13D/13G；所有文件均链接至SEC EDGAR原始申报。
报告期: Q1 2025 ·
方法论 ·
通过API获取此数据